| 股票名称 | 收盘价 | 最低价 | | 创低率 | | --- | --- | --- | --- | --- | | 皓文控股(08019) | 0.130 | 0.130 | -16.13% | | | NIU HOLDINGS(08619) | 0.156 | 0.156 | -11.86% | | | HASHKEY | 5.810 | 5.090 | -9.59% | | | HLDGS(03887) | | | | | | 宋都服务(09608) | 0.068 | 0.060 | -9.09% | | | 瑞科生物－Ｂ(02179) | 5.070 | 5.070 | -5.41% | | | 阳光纸业(02002) | 1.500 | 1.420 | -4.70% | | | 华夏ＳＯＬ(03460) | 5.105 | 4.736 | -3.97% | | | 狮腾控股(02562) | 2.230 | 2.210 | -3.91% | | | 谊砾控股(00076) | 0.174 | 0.160 | -3.61% | | | 卓越商企服务(06989) | 0.830 | 0.83 ...

呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01345 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | USD | | 0.01 | USD | | 30,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 3,000,000,000 | USD | | 0.01 | USD | | 30,000,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海先鋒控股有限公司 本月底法 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海先鋒控股有限公司 呈交日期: 2025年11月6日 | 1. 股份分類 | 普通股 | | 股份類別 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01345 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,257,447,000 | | 0 | | 1,257,447,000 | | 增加 / 減少 (-) | | | | 0 | 0 | | | | 本月底結存 | | | 1,257,447,000 | | 0 | | 1,257,447,000 | 第 2 頁 共 10 頁 v 1.1.1 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01345 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | USD | | 0.01 USD | | 30,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 3,000,000,000 | USD | | 0.01 USD | | 30,000,000 | 本月底法定/註冊股本總額： USD 30,000,000 FF301 公司名稱: ...

Financial Performance - For the six months ended June 30, 2025, the company's revenue was RMB 647.3 million, a decrease of 20.9% compared to RMB 818.0 million in the same period last year[10]. - The gross profit for the same period was RMB 303.0 million, down 13.6% from RMB 350.5 million year-on-year[10]. - The net profit for the six months ended June 30, 2025, was RMB 45.8 million, a decline of 48.1% compared to RMB 88.3 million in the previous year[10]. - Basic earnings per share for the period were RMB 0.04, a decrease of 50.0% from RMB 0.08 in the same period last year[10]. - The revenue for the six months ending June 30, 2024, decreased by 20.9% to RMB 647.3 million from RMB 818.0 million in the previous period[42]. - The revenue from pharmaceutical sales through comprehensive marketing and channel management services decreased by 14.3% to RMB 212.9 million from RMB 248.5 million[42]. - The revenue from medical device sales through comprehensive marketing and channel management services decreased by 12.4% to RMB 374.8 million from RMB 427.7 million[42]. - The gross profit for the six months ending June 30, 2024, decreased by 13.6% to RMB 303.0 million from RMB 350.5 million, while the average gross margin increased to 46.8% from 42.8%[44]. - Other income decreased by 78.7% to RMB 7.6 million from RMB 35.7 million, primarily due to a reduction in government subsidies[45]. - The net profit for the six months ending June 30, 2024, decreased by 48.1% to RMB 45.8 million from RMB 88.3 million, with a net profit margin dropping to 7.1% from 10.8%[51]. - Total comprehensive income for the period was RMB 32,108 thousand, a decrease of 78.1% from RMB 146,638 thousand in the same period last year[87]. - The company reported a net cash outflow from investing activities of RMB 2,969,000, an improvement from RMB 11,712,000 in the previous year[95]. - The company paid dividends amounting to RMB 59,708,000 during the period, compared to RMB 26,263,000 in the previous year[95]. Market and Economic Environment - China's GDP grew by 5.3% in the first half of 2025, indicating a stable economic environment that supports healthcare demand[15]. - The per capita disposable income and consumption expenditure in China increased by 5.4% and 5.3%, respectively, reflecting effective consumer spending potential[15]. - The healthcare expenditure per capita reached RMB 1,314, growing by 3.4% year-on-year, highlighting the increasing health demands among the population[15]. Product Development and Innovation - The company is advancing the localization of innovative medical devices in its Q3 medical series, with factory renovations completed and equipment installation verification underway[13]. - The Chongqing Rongchang production base is a strategic initiative to transform the company into a comprehensive pharmaceutical enterprise integrating R&D, production, and sales[13]. - The company aims to enhance product competitiveness and profitability through the introduction of new technologies and products at the Rongchang production base[13]. - The company is actively promoting the Archimedes biodegradable biliary pancreatic stent, which is the first innovative product registered in mainland China since acquiring Q3 Medical[26]. - A new production line for the Difen® diclofenac sodium dual-release enteric-coated capsule has been launched, with an annual production capacity of 30 million boxes[27]. - The company is actively tracking changes in drug and medical device approval policies in China to expedite the market entry of innovative products, enhancing market competitiveness[31]. Sales and Marketing Strategies - The company is enhancing its sales network and supply chain management to ensure high-quality products reach the market efficiently[18]. - The marketing network has been optimized to improve operational efficiency and mitigate business risks, with a focus on internal sales and academic support teams[32]. - The company plans to enhance its market coverage through precise market positioning and comprehensive marketing strategies, focusing on innovative therapeutic products[40]. - The company continues to focus on expanding its market presence and enhancing its product offerings through integrated marketing and promotion strategies[104]. Investments and Financial Position - The company invested USD 3 million in DMAX Co., Ltd., acquiring a 25% stake, which will strengthen collaboration in promoting zirconia products in China[35]. - The investment in Shanghai Yuhan Fund amounts to RMB 28.5 million, with a 10% partnership interest, focusing on investments in the pharmaceutical sector[36]. - The company holds a 6.62% partnership interest in Jiaxing Yuhan Fund, with an investment of RMB 12.2 million, aimed at long-term growth in the pharmaceutical industry[36]. - The company acquired land use rights for a construction site in Chongqing, covering 38,972 square meters, for RMB 5,998,800, to support future production capabilities[38]. - The company has made significant investments in property, plant, and equipment, totaling RMB 17,942,000 during the period[95]. Compliance and Governance - The company is focusing on compliance management to adapt to regulatory changes and ensure supply chain transparency[18]. - The ongoing regulatory reforms are accelerating the internationalization of China's pharmaceutical distribution industry, enhancing market accessibility for imported innovative drugs[18]. - The company has maintained compliance with corporate governance codes and standards throughout the reporting period[67]. - The company has no significant contingent liabilities as of June 30, 2025[59]. Shareholder Information - The company declared an interim dividend of HKD 0.064 per share, totaling HKD 80,477,000 for the six months ended June 30, 2025[65]. - As of June 30, 2025, the major shareholder Wu Qian holds 833,392,000 shares, representing approximately 66.28% of the company[81]. - The company has a share incentive plan with 98,483,000 shares available for grant, representing approximately 7.83% of the issued shares[72]. - The board granted a total of 25,060,000 shares under the share incentive plan, which automatically lapsed due to non-vesting by October 9, 2018[72]. - The share incentive plan was renewed on April 8, 2025, effective until April 9, 2035[72]. Debt and Liquidity - Total bank borrowings increased from RMB 62.4 million as of December 31, 2024, to RMB 133.2 million as of June 30, 2025, with new long-term bank loans of RMB 89.0 million during the reporting period[57]. - The debt-to-asset ratio increased from 4.3% as of December 31, 2024, to 9.4% as of June 30, 2025[57]. - Cash and cash equivalents increased to RMB 173.6 million as of June 30, 2025, from RMB 103.6 million as of December 31, 2024[52]. - Trade and other payables decreased by 41.1% from RMB 171.2 million as of December 31, 2024, to RMB 100.8 million as of June 30, 2025, with trade payables turnover days reduced from 87.3 days to 47.3 days[56]. Related Party Transactions - Related party transactions included purchases of finished goods from DMAX amounting to RMB 1,208,000, down from RMB 1,662,000 in the previous year[134]. - As of June 30, 2025, the group had receivables from related parties totaling RMB 45,940,000 from Yuyue and RMB 26,194,000 from Earth Master[135].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海先鋒控股有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01345 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | USD | | 0.01 USD | | 30,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 3,000,000,000 | USD | | 0.01 USD | | 30,000,000 | 本月底法定/註冊股本總額： USD 30,000 ...

纯利下跌主要由于报告期内集团所获得的政府补助相较于去年同期显著减少(减少超过人民币3000万 元)。 格隆汇8月29日丨上海先锋控股(01345.HK)公布，2025年上半年，集团收益为人民币6.47亿元，同比减 少20.9%；毛利为人民币3.03亿元，同比减少13.6%；纯利为人民币4580万元，同比减少48.1%。每股基 本盈利为人民币0.04元。 ...

Core Viewpoint - Shanghai Pioneer Holdings (01345) reported a decline in its mid-year performance for 2025, indicating significant challenges in its financial results [1] Financial Performance - The company's revenue for the first half of 2025 was 647 million RMB, representing a year-on-year decrease of 20.87% [1] - Shareholders' profit attributable to the company was 47.736 million RMB, which is a 49.94% decrease compared to the previous year [1] - Basic earnings per share stood at 0.04 RMB [1]

智通财经APP讯，上海先锋控股(01345)发布2025年中期业绩，收益6.47亿元(人民币，下同)，同比减少 20.87%;股东应占溢利4773.6万元，同比减少49.94%;每股基本盈利0.04元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：01345） 截至二零二五年六月三十日止六個月之 中期業績公告 – 1 – • 本集團截至二零二五年六月三十日止六個月的收益為人民幣647.3百 萬 元， 較去年同期人民幣818.0百萬元減少20.9%。 • 本集團截至二零二五年六月三十日止六個月的毛利為人民幣303.0百 萬 元， 較去年同期人民幣350.5百萬元減少13.6%。 • 本集團截至二零二五年六月三十日止六個月的純利為人民幣45.8百 萬 元， 較去年同期人民幣88.3百萬元減少48.1%。 • 本公司截至二零二五年六月三十日止六個月每股基本盈利為人民幣0.04 元，較 去 年 同 期 人 民 幣0.08元減少50.0%。 簡明綜合損益及其他全面收益表 截至二零二五年六月三十日止六個月 截至六月三十日止六個 ...